We serve 4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid CAS:105580-45-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid
CAS.NO: 105580-45-8
Synonyms:
4-(2,3-DICHLORO-PHENYL)-2,6-DIMETHYL-1,4-DIHYDRO-PYRIDINE-3,5-DICARBOXYLIC ACID MONOMETHYL ESTER
Molecular Formula: C16H15Cl2NO4
Molecular Weight: 356.20100
Physical and Chemical Properties:
Density: 1.4±0.1 g/cm3
Boiling point:483.0±45.0 °C at 760 mmHg
Melting point: /
Flash point: 245.9±28.7 °C
Refractive index: 1.581
Specification:
Appearance: White crystal powder
Purity:≥98%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Clevidipine CAS:166432-28-6
Intermediates of Clevidipine butyrate CAS:167221-71-8
Contact us for information like 4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(2,3-DICHLORO-PHENYL)-2,6-DIMETHYL-1,4-DIHYDRO-PYRIDINE-3,5-DICARBOXYLIC ACID MONOMETHYL ESTER physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid Use and application,4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid technical grade,usp/ep/jp grade.
Related News: In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.DL-Homocysteinethiolactone hydrochloride manufacturer In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.5-Acetyl-2,4-dimethylthiazole supplier But now, the metropolis of 11 million in Hubei province has become the face of a deadly coronavirus outbreak — a stigma the people of Wuhan increasingly find themselves unable to shake off.4-Chlorobenzyl pinacolone vendor But now, the metropolis of 11 million in Hubei province has become the face of a deadly coronavirus outbreak — a stigma the people of Wuhan increasingly find themselves unable to shake off.Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.
